The CJC-1295 and ipamorelin combination is the most widely used growth hormone optimization stack, pairing two peptides that stimulate GH release through different receptor pathways. CJC-1295 is a GHRH (growth hormone-releasing hormone) analog that acts on the GHRH receptor, while ipamorelin is a ghrelin receptor (GHS-R) agonist. By activating both pathways simultaneously, the combination is designed to produce a stronger and more sustained GH response than either peptide alone.
This dual-pathway approach mirrors the body's own GH regulation system, where GHRH and ghrelin work together to control pituitary GH secretion. The stack is popular in anti-aging, body composition, and recovery protocols because it elevates GH without the supraphysiological levels associated with exogenous GH injection.
Important: Neither CJC-1295 nor ipamorelin is FDA-approved. They are research compounds. GH optimization protocols should be supervised by a healthcare provider who can monitor IGF-1 levels, blood glucose, and other relevant biomarkers. This guide is for educational purposes only.
When both receptors are activated simultaneously, the GH release is greater than the additive effect of each alone — synergistic potentiation.
The peptides
Why these work together
Growth hormone release from the pituitary is controlled by two opposing systems: GHRH stimulates release, and somatostatin inhibits it. Within the stimulatory side, GHRH and ghrelin activate GH release through separate receptor pathways that converge on the somatotroph cells of the anterior pituitary.
CJC-1295 acts as a GHRH analog, binding the GHRH receptor and signaling the pituitary to release GH. Ipamorelin acts as a ghrelin-pathway agonist, binding the GHS-R receptor on the same somatotroph cells. When both receptors are activated simultaneously, the GH release is greater than the additive effect of each alone — a phenomenon documented in pharmacological studies as synergistic potentiation.
This synergy is why the combination is preferred over higher doses of either peptide individually. Doubling the dose of CJC-1295 alone produces diminishing returns due to somatostatin feedback, while adding ipamorelin circumvents this feedback through a separate signaling cascade. The result is a stronger, more physiological GH pulse pattern with fewer off-target hormonal effects than less selective alternatives like GHRP-6 or hexarelin.
Suggested protocol
Begin with standard doses twice daily to assess tolerance. The before-bed dose is most important — it amplifies the natural nocturnal GH pulse.
Increase to 2–3 doses daily for maximum GH pulsatility. Add a post-workout dose on training days. Always administer on an empty stomach.
Reduce to once daily (before bed only) for 2 weeks, then take a 4-week break from both peptides to prevent receptor desensitization.
Safety considerations
Water retention, joint stiffness, tingling in extremities. May affect insulin sensitivity with prolonged use. Monitor IGF-1 levels.
Head rush after injection, water retention, mild joint stiffness. Well-tolerated relative to other GH secretagogues. No completed human clinical trials.
The combination of all three peptides has never been studied in clinical trials. Additive side effects, drug interactions, and long-term safety are unknown. Not appropriate for individuals with active or prior pancreatitis, MEN 2 syndrome, active cancer, or during pregnancy/breastfeeding. Physician supervision is essential.
Frequently asked questions
This stack stimulates your pituitary gland to release more growth hormone through two complementary pathways — CJC-1295 via the GHRH receptor and ipamorelin via the ghrelin receptor. The combined effect is a stronger, more sustained GH pulse than either peptide produces alone. Elevated GH supports recovery, body composition, sleep quality, and overall vitality.
CJC-1295 with DAC has a long half-life (6-8 days) and produces sustained, elevated baseline GH — convenient (weekly dosing) but less physiological. CJC-1295 without DAC (Mod GRF 1-29) has a short half-life (30 minutes) and produces acute GH pulses that more closely mimic natural secretion patterns. The without-DAC variant is more commonly paired with ipamorelin for a natural pulsatile pattern.
The most important dose is before bed, as it amplifies the natural nocturnal GH pulse. Additional doses can be taken upon waking or post-workout. Always administer on an empty stomach — carbohydrates and fats suppress GH release. Wait at least 20-30 minutes after injection before eating.
Improved sleep quality is often reported within the first 1-2 weeks. Body composition changes (reduced body fat, improved muscle tone) typically become noticeable after 6-8 weeks of consistent use alongside training and proper nutrition. Skin and recovery improvements are commonly reported in the 4-8 week range.
Both peptides are generally considered well-tolerated based on available data. Ipamorelin is notably selective, with minimal impact on cortisol, prolactin, or appetite. Common side effects include water retention, joint stiffness, and tingling. However, long-term safety data from human clinical trials is lacking. Blood glucose and IGF-1 levels should be monitored during use. Consult a healthcare provider before starting any GH-optimization protocol.